Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Desonide Cream, 0.05%, the generic version of Desonide Cream, 0.05% of Perrigo New York Inc.

According to IMS Health sales data for the 12 month period ending May 2017, the Desonide Cream, 0.05% market achieved annual sales of approximately USD 44.6 million.

Glenmark's current portfolio consists of 120 products authorized for distribution in the U.S. marketplace and 65 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of the company gained Rs 3.2, or 0.46%, to trade at Rs 692.10. The total volume of shares traded was 4,345 at the BSE (9.36 a.m., Tuesday).